Urothelial Carcinoma Clinical Trials in Cleveland, Ohio

6 studies are recruiting for urothelial carcinoma in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

   This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cleveland Clinic, Cleveland, Ohio

   Locations

   8 in total

   Run by

   Deciphera Pharmaceuticals, LLC

   See if you can join NCT06966024 on ClinicalTrials.gov

2. Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

   This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University Hospitals Cleveland Medical Center, Cleveland, Ohio

   Locations

   153 in total

   Run by

   Pfizer

   See if you can join NCT07421700 on ClinicalTrials.gov

3. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cleveland Clinic, Cleveland, Ohio

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

4. A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

   This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanc…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University Hospitals Cleveland Medical Center, Cleveland, Ohio

   Locations

   221 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT04879329 on ClinicalTrials.gov

5. A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

   This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cleveland Clinic-Taussig Cancer Center ( Site 1036), Cleveland, Ohio

   Locations

   28 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05562830 on ClinicalTrials.gov

6. Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

   The goal of this study is to conduct the first randomized-controlled trial to determine the oncologic efficacy of lymph node dissection in participants with upper tract urothelial cell carcinoma. The main questions it aims to answer are: * To determine oncologic outcomes, specifically 2-year recurr…

   Stage

   Not phased

   Ages

   19 and older

   Site

   University Hospitals Cleveland Medical Center, Urology Institute, Case Comprehensive Cancer Center, Cleveland, Ohio

   Locations

   4 in total

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT06262516 on ClinicalTrials.gov